Investment Thesis
Processa Pharmaceuticals is a pre-revenue pharmaceutical company with $11.4M in annual operating cash burn against only $5.5M in cash reserves, implying a runway of approximately six months at current burn rates. Despite a clean balance sheet with minimal debt, the absence of revenue generation combined with an unsustainable burn rate presents fundamental financial distress incompatible with any positive investment thesis.
Strengths
- Minimal debt burden with Debt/Equity ratio near zero and only $27.5K long-term debt
- Strong short-term liquidity with Current Ratio of 2.54x and Quick Ratio of 2.47x
- Modest 89.3% YoY improvement in diluted EPS trajectory suggesting operational optimization
Risks
- Zero revenue with no visible commercialization pathway or production capability
- Critical cash runway of approximately six months at current $11.4M annual burn rate
- High pharmaceutical R&D execution risk with uncertain clinical pipeline and regulatory approval uncertainty
- Dependence on future capital raises to survive, creating severe dilution risk to equity
Key Metrics to Watch
- Quarterly cash balance and updated runway projections relative to burn rate
- Clinical trial milestones, FDA interactions, and regulatory pathway clarity
- Debt or equity financing announcements and capital structure changes
Financial Metrics
Revenue
0.0
Net Income
-13.6M
EPS (Diluted)
$-10.36
Free Cash Flow
-11.4M
Total Assets
7.8M
Cash
5.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-243.2%
ROA
-173.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.54x
Quick Ratio
2.47x
Debt/Equity
0.00x
Debt/Assets
28.6%
Interest Coverage
-38,642.28x
Long-term Debt
27.5K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T02:42:26.311764 |
Data as of: 2025-12-31 |
Powered by Claude AI